Glenmark Pharmaceuticals Ltd (GLENMARK):企業の財務・戦略的SWOT分析

◆英語タイトル:Glenmark Pharmaceuticals Ltd (GLENMARK) - Financial and Strategic SWOT Analysis Review
◆商品コード:SWOT20MY0432
◆発行会社(調査会社):GlobalData
◆発行日:2019年12月
◆ページ数:56
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:インド
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥18,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Glenmark Pharmaceuticals Ltd (GLENMARK) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Glenmark Pharmaceuticals Ltd (Glenmark) focuses on the discovery of new chemical entities (NCEs) and new biological entities (NBEs). The company’s formulations business encompasses therapeutic areas such as dermatology, anti-infective, respiratory, central nervous system, and oncology. It also offers a wide range of generic products. The company manufactures and supplies active pharmaceutical ingredients (APIs). Glenmark developed a proprietary platform, Bispecific Engagement by antibodies based on the T-cell receptor (BEAT) for production of bispecific antibodies. The company markets its products in North America, South America, Asia-Pacific and Africa. Glenmark is headquartered in Mumbai, Maharashtra, India.

Glenmark Pharmaceuticals Ltd Key Recent Developments

Nov 14,2019: Glenmark’s consolidated revenue rises 9.05% to Rs. 28,150.4 Mn. in Q2 FY 2019-20
Oct 05,2019: Glenmark Pharmaceuticals: Update on the US FDA inspection of Glenmark’s Baddi manufacturing facility in Himachal Pradesh
Oct 03,2019: US FDA issues warning letter to Glenmark Pharmaceuticals
Aug 13,2019: Glenmark’s consolidated revenue atRs.23,228.79 Mn.for Q1 FY 2019–20
May 07,2019: Glenmark appoints Dr. Yasir Rawjee as chief executive officer of Glenmark Life Sciences, its subsidiary for the API business

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Glenmark Pharmaceuticals Ltd – Key Facts
Glenmark Pharmaceuticals Ltd – Key Employees
Glenmark Pharmaceuticals Ltd – Key Employee Biographies
Glenmark Pharmaceuticals Ltd – Major Products and Services
Glenmark Pharmaceuticals Ltd – History
Glenmark Pharmaceuticals Ltd – Company Statement
Glenmark Pharmaceuticals Ltd – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Glenmark Pharmaceuticals Ltd – Business Description
Product Category: Other Operating Revenue
Performance
Product Category: Sale of Products
Performance
Product Category: Sale of Services
Performance
Geographical Segment: Europe
Performance
Geographical Segment: India
Performance
Geographical Segment: Latin America
Performance
Geographical Segment: Rest of the World (ROW)
Performance
Geographical Segment: USA
Performance
R&D Overview
Glenmark Pharmaceuticals Ltd – Corporate Strategy
Glenmark Pharmaceuticals Ltd – SWOT Analysis
SWOT Analysis – Overview
Glenmark Pharmaceuticals Ltd – Strengths
Glenmark Pharmaceuticals Ltd – Weaknesses
Glenmark Pharmaceuticals Ltd – Opportunities
Glenmark Pharmaceuticals Ltd – Threats
Glenmark Pharmaceuticals Ltd – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Glenmark Pharmaceuticals Ltd, Recent Deals Summary
Section 5 – Company’s Recent Developments
Nov 14, 2019: Glenmark’s consolidated revenue rises 9.05% to Rs. 28,150.4 Mn. in Q2 FY 2019-20
Oct 05, 2019: Glenmark Pharmaceuticals: Update on the US FDA inspection of Glenmark’s Baddi manufacturing facility in Himachal Pradesh
Oct 03, 2019: US FDA issues warning letter to Glenmark Pharmaceuticals
Aug 13, 2019: Glenmark’s consolidated revenue atRs.23,228.79 Mn.for Q1 FY 2019–20
May 07, 2019: Glenmark appoints Dr. Yasir Rawjee as chief executive officer of Glenmark Life Sciences, its subsidiary for the API business
Mar 28, 2019: Glenmark: Intimation of Appointment of Ms. Sona Saira Ramasastry as an Additional Director – independent Director
Mar 06, 2019: Glenmark Pharmaceuticals appoints Alessandro Riva as CEO of its new innovation company
Feb 15, 2019: Glenmark Pharmaceuticals to establish new company in US
Feb 14, 2019: Glenmark’s consolidated revenue rises 15.95% to Rs. 25,550.45 Mn. in Q3 FY 2018 – 19
Dec 19, 2018: Glenmark Pharmaceuticals announces entry into branded dermatology segment in the United States
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Glenmark Pharmaceuticals Ltd, Key Facts
Glenmark Pharmaceuticals Ltd, Key Employees
Glenmark Pharmaceuticals Ltd, Key Employee Biographies
Glenmark Pharmaceuticals Ltd, Major Products and Services
Glenmark Pharmaceuticals Ltd, History
Glenmark Pharmaceuticals Ltd, Other Locations
Glenmark Pharmaceuticals Ltd, Subsidiaries
Glenmark Pharmaceuticals Ltd, Key Competitors
Glenmark Pharmaceuticals Ltd, Ratios based on current share price
Glenmark Pharmaceuticals Ltd, Annual Ratios
Glenmark Pharmaceuticals Ltd, Annual Ratios (Cont...1)
Glenmark Pharmaceuticals Ltd, Annual Ratios (Cont...2)
Glenmark Pharmaceuticals Ltd, Interim Ratios
Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Glenmark Pharmaceuticals Ltd, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Glenmark Pharmaceuticals Ltd, Performance Chart (2015 - 2019)
Glenmark Pharmaceuticals Ltd, Ratio Charts
Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

★海外企業調査レポート[Glenmark Pharmaceuticals Ltd (GLENMARK):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Indra Sistemas, S.A.:企業の戦略・SWOT・財務分析
    Indra Sistemas, S.A. - Strategy, SWOT and Corporate Finance Report Summary Indra Sistemas, S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Petrol dd Ljubljana (PETG):石油・ガス:M&Aディール及び事業提携情報
    Summary Petrol dd Ljubljana (Petrol dd) is an energy company. It markets and distributes oil and petroleum products, electricity, heat, merchandise, natural gas and liquefied petroleum gas (LPG). The company sells automotive products, foodstuffs, accessories, tobacco, and chemical products. Petrol d …
  • Kansas City Deaerator Co:企業の戦略的SWOT分析
    Kansas City Deaerator Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Laboratoires Pierre Fabre SA:企業の戦略的SWOT分析
    Laboratoires Pierre Fabre SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • MedImmune Ltd-製薬・医療分野:企業M&A・提携分析
    Summary MedImmune Ltd (MedImmune), formerly Cambridge Antibody Technology Ltd, is a subsidiary of AstraZeneca Plc, is a research and development company that develops and commercializes small molecule and biologic prescription medicines for the prevention of respiratory tract disease caused by respi …
  • Samsung Biologics Co Ltd (207940):製薬・医療:M&Aディール及び事業提携情報
    Summary Samsung Biologics Co Ltd (Samsung Biologics) is a biologics development and manufacturing company. The company’s business activities include process development, contract manufacturing, aseptic fill and finish and project management. Samsung Biologics cell culture development process include …
  • Analytik Jena AG:医療機器:M&Aディール及び事業提携情報
    Summary Analytik Jena AG (Analytik Jena), a subsidiary of Endress+Hauser AG is a provider of instruments and products for analytical measuring technology and life science. The company’s major products include atomic spectrometers, optical emission spectroscopy devices, mass spectrometers, mercury an …
  • Avangrid Inc (AGR):企業の財務・戦略的SWOT分析
    Avangrid Inc (AGR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Xcel Energy Inc (XEL):石油・ガス:M&Aディール及び事業提携情報
    Summary Xcel Energy Inc. (Xcel Energy) is a vertically-integrated energy utility that generates, procures, transmits, distributes and sells electricity; and transports, stores and distributes natural gas through its subsidiaries. The company owns and operates generation assets utilizing diverse fuel …
  • Barnwell Industries Inc Oil & Gas Exploration and Production Operations and Cost Analysis – 2017
    Barnwell Industries Inc Oil & Gas Exploration and Production Operations and Cost Analysis - 2017 Summary Barnwell Industries Inc (Barnwell) is a diversified company. The company's business activities include oil and natural gas, land investment, and contract drilling. Its oil and natural gas divisio …
  • New Zealand Pharmaceuticals Ltd:企業の戦略的SWOT分析
    New Zealand Pharmaceuticals Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • Matisa Materiel Industriel S.A.:企業の戦略・SWOT・財務分析
    Matisa Materiel Industriel S.A. - Strategy, SWOT and Corporate Finance Report Summary Matisa Materiel Industriel S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Isagen SA ESP-エネルギー分野:企業M&A・提携分析
    Summary Isagen SA ESP (Isagen), a subsidiary of Brookfield Renewable Energy Partners LP, is an electricity utility. It generates and markets electricity; supplies natural gas; and sells coal, steam, and other energy sources. The company produces electric energy from hydro and natural gas sources. Is …
  • Ardelyx Inc (ARDX):製薬・医療:M&Aディール及び事業提携情報
    Summary Ardelyx Inc (Ardelyx) is a developer of small molecule therapeutics for treatment of cardio-renal, gastrointestinal and metabolic disorders. The company provides product portfolio such as tenapanor, RDX227675, RDX98940 and RDX013, among others. Its products are used for hyperphosphatemia in …
  • EryDel SPA:製薬・医療:M&Aディール及び事業提携情報
    Summary EryDel SPA (EryDel), a subsidiary of Genextra Spa is a drug delivery company that develops drugs and diagnostics delivered through human red blood cells using a proprietary medical device technology. The company’s products include red cell loaders, and disposable kits for drug encapsulation …
  • SMBC Trust Bank Private Banking:企業の戦略・SWOT・財務分析
    SMBC Trust Bank Private Banking - Strategy, SWOT and Corporate Finance Report Summary SMBC Trust Bank Private Banking - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Antisense Therapeutics Ltd (ANP):企業の財務・戦略的SWOT分析
    Antisense Therapeutics Ltd (ANP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Owens & Minor Inc (OMI):製薬・医療:M&Aディール及び事業提携情報
    Summary Owens & Minor Inc (Owens & Minor) is a healthcare services company, which provides supply chain services to healthcare providers and manufacturers of healthcare products. It provides logistics services for disposable medical supplies, devices and implants. Owens & Minor offers medical and su …
  • Yeda Research and Development Company Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Yeda Research and Development Company Ltd (Yeda), a subsidiary of Weizmann Institute of Science is a technology transfer company that provides research and science education. The company identifies and assesses research projects with commercial potential, protects the intellectual property o …
  • Harbin Bank Co Ltd:企業の戦略・SWOT・財務分析
    Harbin Bank Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Harbin Bank Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆